| Bioactivity | UCB-J is a positron emission tomography (PET) radioligand for the synaptic vesicle protein 2A (SV2A)[1][2][3][4]. |
| In Vivo | UCB-J exhibits high free fraction (0.46 ± 0.02) and metabolizes at a moderate rate (39% ± 5% and 24% ± 3% parent remaining at 30 and 90 min) in plasma[3]. UCB-J displays high uptake and fast kinetics in the monkey brain[3]. When the animal is pretreated with UCB-J (150 μg/kg, iv), the whole brain SUV decreases to the same level as centrum semiovale, indicating the in vivo binding specificity of [18F]7 to SV2A[4]. |
| Name | UCB-J |
| CAS | 2242957-52-2 |
| Formula | C17H15F3N2O |
| Molar Mass | 320.31 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Joël Mercier, et al. Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single-digit nanomolar potency: opening avenues towards the first SV2A positron emission tomography (PET) ligands. ChemMedChem. 2014 Apr;9(4):693-8. [2]. Aline Delva, et al. Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease. Mov Disord. 2020 Aug 7. [3]. Nabeel B Nabulsi, et al. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain. J Nucl Med. 2016 May;57(5):777-84. [4]. Zhengxin Cai, et al. Synthesis and Preclinical Evaluation of an 18 F-Labeled Synaptic Vesicle Glycoprotein 2A PET Imaging Probe: [ 18 F]SynVesT-2. ACS Chem Neurosci. 2020 Feb 19;11(4):592-603. |